This post was originally published on this site
ZURICH (Reuters) – Swiss drugmaker Novartis is confident to reach a core margin in innovative medicines in the high 30s by 2026 and grow sales by 4% each year until the end of that period, the company said in a presentation on Thursday.
Novartis added it had up to 20 assets in its pipeline with approval expected by 2026 that had the potential to generate at least 1$ billion in sales.
